Patents Assigned to Shattuck Labs, Inc.
  • FLT3L-based chimeric proteins
    Patent number: 11896618
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: February 13, 2024
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Heterodimeric proteins and uses thereof
    Patent number: 11780897
    Abstract: The present invention relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: October 10, 2023
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Heterodimeric proteins for modulating gamma delta T cells
    Patent number: 11643447
    Abstract: The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: May 9, 2023
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Methods of making and using extracellular domain-based chimeric proteins
    Patent number: 11332509
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins and combination therapies that find use in the treatment of disease, such as cancer and/or an inflammatory disease.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: May 17, 2022
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • CSF1R-CD40L chimeric proteins
    Patent number: 11267856
    Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: March 8, 2022
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • CSF1R-based chimeric proteins
    Patent number: 11267857
    Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: March 8, 2022
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • VSIG8-based chimeric proteins
    Patent number: 11192933
    Abstract: The present invention relates, in part, to chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for cancer and/or inflammatory diseases.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: December 7, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • VSIG8-based chimeric proteins
    Patent number: 11192934
    Abstract: The present invention relates, in part, to chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for cancer and/or inflammatory diseases.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: December 7, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Heterodimeric proteins for modulating gamma delta T cells
    Patent number: 11098093
    Abstract: The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: August 24, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Heterodimeric proteins and uses thereof
    Patent number: 10995127
    Abstract: The present invention relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: May 4, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Heterodimeric proteins for modulating gamma delta T cells
    Patent number: 10988517
    Abstract: The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: April 27, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • TIGIT- and light-based chimeric proteins
    Patent number: 10927159
    Abstract: The present invention relates, inter alia, to compositions and methods, including TIGIT- and/or LIGHT-based chimeric proteins that find use in the treatment of disease, such as cancer and an inflammatory disease.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: February 23, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • TIGIT- and light-based chimeric proteins
    Patent number: 10899817
    Abstract: The present invention relates, inter alia, to compositions and methods, including TIGIT- and/or LIGHT-based chimeric proteins that find use in the treatment of disease, such as cancer and an inflammatory disease.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: January 26, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • FLT3L-based chimeric proteins
    Patent number: 10780121
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: September 22, 2020
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • CSF1R-based chimeric proteins
    Patent number: 10513548
    Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: December 24, 2019
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva